DE60144240D1 - Zusammensetzung mit immunogenen mikroteilchen - Google Patents
Zusammensetzung mit immunogenen mikroteilchenInfo
- Publication number
- DE60144240D1 DE60144240D1 DE60144240T DE60144240T DE60144240D1 DE 60144240 D1 DE60144240 D1 DE 60144240D1 DE 60144240 T DE60144240 T DE 60144240T DE 60144240 T DE60144240 T DE 60144240T DE 60144240 D1 DE60144240 D1 DE 60144240D1
- Authority
- DE
- Germany
- Prior art keywords
- microparticles
- composition
- immunogenic microparticles
- provides
- immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011859 microparticle Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR0117A AUPR011700A0 (en) | 2000-09-14 | 2000-09-14 | Composition comprising immunogenic virus sized particles (VSP) |
AUPR4888A AUPR488801A0 (en) | 2001-05-10 | 2001-05-10 | Composition comprising immunogenic virus sized particles (vsp) |
AUPR4962A AUPR496201A0 (en) | 2001-05-14 | 2001-05-14 | Composition comprising immunogenic virus sized particles (VSP) |
PCT/AU2001/001160 WO2002022164A1 (en) | 2000-09-14 | 2001-09-14 | Composition comprising immunogenic microparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60144240D1 true DE60144240D1 (de) | 2011-04-28 |
Family
ID=27158243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60144240T Expired - Lifetime DE60144240D1 (de) | 2000-09-14 | 2001-09-14 | Zusammensetzung mit immunogenen mikroteilchen |
Country Status (15)
Country | Link |
---|---|
US (3) | US20040014708A1 (de) |
EP (1) | EP1326633B1 (de) |
JP (1) | JP5198712B2 (de) |
KR (1) | KR20030055262A (de) |
CN (1) | CN100446811C (de) |
AT (1) | ATE501726T1 (de) |
AU (1) | AUPR011700A0 (de) |
CA (1) | CA2422575C (de) |
DE (1) | DE60144240D1 (de) |
DK (1) | DK1326633T3 (de) |
ES (1) | ES2363735T3 (de) |
IL (1) | IL154913A0 (de) |
NZ (2) | NZ524843A (de) |
PT (1) | PT1326633E (de) |
WO (1) | WO2002022164A1 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
FR2844514B1 (fr) | 2002-09-16 | 2007-10-19 | Neovacs | Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation |
CA2525519A1 (en) * | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
WO2005053740A1 (ja) * | 2003-12-02 | 2005-06-16 | Bio Matrix Research Inc. | 免疫増強剤およびこれを用いた強化抗原 |
WO2006012695A1 (en) * | 2004-08-04 | 2006-02-09 | Panvax Limited | An immunogenic composition |
EP1932538A4 (de) * | 2005-08-25 | 2009-10-21 | Taiho Pharmaceutical Co Ltd | Biologisch abbaubare nanoteilchen mit darauf immobilisiertem oder darin verkapseltem t-zell-erkennbarem epitop-peptid |
WO2008150276A2 (en) * | 2006-09-26 | 2008-12-11 | The Board Of Regents Of The University Of Texas System | Virus coated nanoparticles and uses thereof |
RU2016137258A (ru) | 2009-04-01 | 2018-12-13 | Юниверсити Оф Майами | Композиции вакцин и способы их применения |
CN110542754A (zh) * | 2009-05-19 | 2019-12-06 | 迈阿密大学 | 用于体外抗原呈递、评估疫苗功效及生物制剂和药物的免疫毒性的组合物、试剂盒和方法 |
SG178144A1 (en) * | 2009-07-29 | 2012-03-29 | Bernd Helmut Adam Rehm | Polymer particles and uses thereof |
DK2635257T3 (en) | 2010-11-05 | 2017-09-04 | Novavax Inc | Rabies virus-like glycoprotein particles (VLP) |
US20120189700A1 (en) * | 2011-01-19 | 2012-07-26 | Zoraida Aguilar | Nanoparticle Based Immunological Stimulation |
CN103857387B (zh) * | 2011-06-02 | 2017-03-15 | 加利福尼亚大学董事会 | 膜包封的纳米颗粒及使用方法 |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
WO2015021390A2 (en) | 2013-08-08 | 2015-02-12 | The Regents Of The University Of California | Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis |
US10098839B2 (en) | 2014-03-20 | 2018-10-16 | The Regents Of The University Of California | Hydrogel toxin-absorbing or binding nanoparticles |
IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
CN107708811B (zh) | 2015-04-21 | 2021-04-30 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
CN107530285B (zh) | 2015-04-29 | 2021-07-27 | 加利福尼亚大学董事会 | 使用纳米粒子解毒 |
JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
CN109200271B (zh) * | 2018-11-14 | 2021-01-29 | 江南大学 | 一种蛋白质及其在调控巨噬细胞免疫功能方面的应用 |
WO2020257315A1 (en) * | 2019-06-18 | 2020-12-24 | Citranvi Biosciences, Llc | Multiple antigen protein displayed adjuvant systems |
US20220273790A1 (en) * | 2019-06-18 | 2022-09-01 | Citranvi Biosciences, Llc | Rationally engineered carrier proteins for vaccines |
CN110339350A (zh) * | 2019-07-25 | 2019-10-18 | 广州中科蓝华生物科技有限公司 | 一种抗肿瘤的联合用药物组合物及其应用 |
AU2021319206A1 (en) * | 2020-07-31 | 2023-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Vaccine compositions and methods of use thereof |
WO2024097307A1 (en) * | 2022-11-01 | 2024-05-10 | Lupagen, Inc. | Devices and methods for extracorporeal cell treatment |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK143689C (da) * | 1975-03-20 | 1982-03-15 | J Kreuter | Fremgangsmaade til fremstilling af en adsorberet vaccine |
US4035316A (en) * | 1975-11-24 | 1977-07-12 | California Institute Of Technology | Cell specific, variable density, polymer microspheres |
US4170685A (en) * | 1976-03-29 | 1979-10-09 | California Institute Of Technology | Polyvinyl pyridine microspheres |
US4157323A (en) * | 1976-06-09 | 1979-06-05 | California Institute Of Technology | Metal containing polymeric functional microspheres |
US4247434A (en) * | 1978-12-29 | 1981-01-27 | Lovelace Alan M Administrator | Process for preparation of large-particle-size monodisperse |
US4438239A (en) * | 1981-03-30 | 1984-03-20 | California Institute Of Technology | Microsphere coated substrate containing reactive aldehyde groups |
SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
US4828984A (en) * | 1986-04-11 | 1989-05-09 | Flow Cytometry Standards Corporation | Composition, synthesis and use of simulated cells |
US6338853B1 (en) | 1987-04-23 | 2002-01-15 | Jean-Claude Bystryn | Anti-cancer vaccine |
US5002883A (en) * | 1987-10-30 | 1991-03-26 | Abbott Laboratories | Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5443832A (en) * | 1990-04-16 | 1995-08-22 | Institut Swisse De Recherches Experimentales Sur Le Cancer | Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response |
US5219577A (en) * | 1990-06-22 | 1993-06-15 | The Regents Of The University Of California | Biologically active composition having a nanocrystalline core |
US5334394A (en) * | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
US5178882A (en) * | 1990-06-22 | 1993-01-12 | The Regents Of The University Of California | Viral decoy vaccine |
US5665582A (en) * | 1990-10-29 | 1997-09-09 | Dekalb Genetics Corp. | Isolation of biological materials |
US5688761A (en) * | 1991-04-19 | 1997-11-18 | Lds Technologies, Inc. | Convertible microemulsion formulations |
US6129916A (en) * | 1991-04-19 | 2000-10-10 | Tanox, Inc. | Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates |
FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
EP0678034B1 (de) * | 1993-01-11 | 1999-05-26 | Dana Farber Cancer Institute | Induktion der antworten zytotoxischer t-lymphozyten |
US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
EP1181937A3 (de) * | 1994-08-09 | 2004-02-04 | Cytrx Corporation | Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans |
AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
WO1996014855A1 (en) | 1994-11-15 | 1996-05-23 | Agracetus, Inc. | Method for inducing humoral and cellular immune responses utilizing intracellular delivery of peptide-coated microparticles |
ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
AU714584B2 (en) * | 1995-07-21 | 2000-01-06 | Brown University Research Foundation | A method for gene therapy using nucleic acid loaded polymeric microparticles |
KR20000067855A (ko) * | 1996-07-10 | 2000-11-25 | 웨스트 파머슈티컬 서비스 드러그 딜리버리 앤드 크리니컬 리써치 센터 리미티드 | 내피표적용 유전자치료제 전달시스템 |
US5789261A (en) * | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
CA2279204C (en) | 1997-01-30 | 2005-11-15 | Chiron Corporation | Use of microparticles with adsorbed antigen to stimulate immune responses |
AU760034B2 (en) | 1997-08-29 | 2003-05-08 | Corixa Corporation | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof |
US6001333A (en) | 1997-09-12 | 1999-12-14 | See; Jackie R. | Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging |
ATE281844T1 (de) | 1998-01-16 | 2004-11-15 | Univ Johns Hopkins | Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe |
SE9800615D0 (sv) | 1998-02-27 | 1998-02-27 | Ingvar Sjoeholm | Mucosal microparticle conjugate vaccine |
GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
WO2000012124A1 (en) | 1998-09-01 | 2000-03-09 | Elan Corporation, Plc | Oral vaccine compositions |
ES2228467T3 (es) * | 1999-02-03 | 2005-04-16 | Biosante Pharmaceuticals, Inc. | Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso. |
CA2362578A1 (en) | 1999-02-09 | 2000-08-17 | Kam Leong | Tumor vaccines |
AU3730600A (en) * | 1999-03-18 | 2000-10-04 | Xiaojiang Chen | Compositions preparations and uses of human papillomavirus l1 protein |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
AU4373499A (en) | 1999-06-02 | 2000-12-28 | Medinova Medical Consulting Gmbh | Use of drug-loaded nanoparticles for the treatment of cancers |
EP1118331A1 (de) | 2000-01-21 | 2001-07-25 | I.D.M. Immuno-Designed Molecules | Verfahren zur Verstärkung der Präsentation exogener Antigene durch menschlische Antigen-präsentierende Zellen und opsonisierte Mikropartikelkomplexe zur Anwendung dieser Methode |
AU780182B2 (en) | 2000-03-22 | 2005-03-03 | Secretary Of State For Defence, The | Pharmaceutical composition for administration to mucosal surfaces |
AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
FR2859909B1 (fr) | 2003-09-22 | 2007-09-07 | Biomerieux Sa | Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation |
AU2004289210B2 (en) | 2003-11-05 | 2010-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
EP1697511A4 (de) | 2003-12-11 | 2007-11-21 | Vaxdesign Corp | Immuntherapiezusammensetzungen, verfahren zur herstellung und verfahren zur verwendung davon |
EP1954252B1 (de) | 2005-12-02 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Nanopartikel für den einsatz in immunogenen zusammensetzungen |
US8021689B2 (en) | 2006-02-21 | 2011-09-20 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | Nanoparticles for immunotherapy |
CA2643322C (en) | 2006-02-24 | 2015-07-21 | Novartis Ag | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
WO2007148048A1 (en) | 2006-06-20 | 2007-12-27 | Cmp Therapeutics Limited | Compositions comprising chitin microparticles and their medical uses |
WO2008022253A2 (en) | 2006-08-16 | 2008-02-21 | Temple University-Of The Commonwealth System Of Higher Education | An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions |
WO2008082439A2 (en) | 2006-08-28 | 2008-07-10 | Duke University | Antigen specific nanoparticles |
AT504160A1 (de) | 2006-09-11 | 2008-03-15 | Ralf Dr Kircheis | Verwendung einer mehrkomponenten-tumorvakzine |
US20100151031A1 (en) | 2007-03-23 | 2010-06-17 | Desimone Joseph M | Discrete size and shape specific organic nanoparticles designed to elicit an immune response |
MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
US9107858B2 (en) | 2007-12-05 | 2015-08-18 | Wisconsin Alumni Research Foundation | Dendritic cell targeting compositions and uses thereof |
CA2716622A1 (en) | 2008-02-26 | 2009-09-03 | The Regents Of The University Of California | Glycopeptides and methods of making and using them |
CA2750098A1 (en) | 2009-01-20 | 2010-07-29 | Myelin Repair Foundation, Inc. | Compositions and methods for induction of antigen-specific tolerance |
-
2000
- 2000-09-14 AU AUPR0117A patent/AUPR011700A0/en not_active Abandoned
-
2001
- 2001-09-14 CN CNB018156452A patent/CN100446811C/zh not_active Expired - Fee Related
- 2001-09-14 IL IL15491301A patent/IL154913A0/xx unknown
- 2001-09-14 US US10/380,588 patent/US20040014708A1/en not_active Abandoned
- 2001-09-14 CA CA2422575A patent/CA2422575C/en not_active Expired - Fee Related
- 2001-09-14 DK DK01966829.2T patent/DK1326633T3/da active
- 2001-09-14 EP EP01966829A patent/EP1326633B1/de not_active Expired - Lifetime
- 2001-09-14 PT PT01966829T patent/PT1326633E/pt unknown
- 2001-09-14 NZ NZ524843A patent/NZ524843A/en not_active IP Right Cessation
- 2001-09-14 ES ES01966829T patent/ES2363735T3/es not_active Expired - Lifetime
- 2001-09-14 JP JP2002526413A patent/JP5198712B2/ja not_active Expired - Fee Related
- 2001-09-14 KR KR10-2003-7003743A patent/KR20030055262A/ko not_active Application Discontinuation
- 2001-09-14 AT AT01966829T patent/ATE501726T1/de active
- 2001-09-14 WO PCT/AU2001/001160 patent/WO2002022164A1/en active IP Right Grant
- 2001-09-14 DE DE60144240T patent/DE60144240D1/de not_active Expired - Lifetime
- 2001-09-14 NZ NZ535851A patent/NZ535851A/en not_active IP Right Cessation
-
2009
- 2009-10-21 US US12/603,439 patent/US8287877B2/en not_active Expired - Fee Related
-
2011
- 2011-10-27 US US13/283,294 patent/US8846026B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2363735T3 (es) | 2011-08-12 |
PT1326633E (pt) | 2011-06-29 |
CN100446811C (zh) | 2008-12-31 |
ATE501726T1 (de) | 2011-04-15 |
AUPR011700A0 (en) | 2000-10-05 |
US20040014708A1 (en) | 2004-01-22 |
CA2422575A1 (en) | 2002-03-21 |
KR20030055262A (ko) | 2003-07-02 |
NZ524843A (en) | 2004-11-26 |
US20100136043A1 (en) | 2010-06-03 |
CA2422575C (en) | 2015-04-28 |
EP1326633A1 (de) | 2003-07-16 |
JP5198712B2 (ja) | 2013-05-15 |
US20120082725A1 (en) | 2012-04-05 |
NZ535851A (en) | 2006-04-28 |
US8846026B2 (en) | 2014-09-30 |
US8287877B2 (en) | 2012-10-16 |
EP1326633A4 (de) | 2006-05-24 |
CN1630531A (zh) | 2005-06-22 |
DK1326633T3 (da) | 2011-07-04 |
EP1326633B1 (de) | 2011-03-16 |
JP2004507566A (ja) | 2004-03-11 |
WO2002022164A1 (en) | 2002-03-21 |
IL154913A0 (en) | 2003-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE501726T1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
WO2005037190A3 (en) | Multiplex vaccines | |
DK1635863T3 (da) | Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål | |
WO2004030608A3 (en) | Nanoemulsion vaccines | |
TR200102739T2 (tr) | Aşı | |
EP1594536A4 (de) | Adjuvante influenza-vakzine | |
IL150602A (en) | Proteosome influenza vaccine, method for preparing such and use thereof | |
WO2007068907A3 (en) | Vaccine compositions comprising a saponin adjuvant | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
WO2004032829A3 (en) | Immunostimulatory compositions and methods of stimulating an immune response | |
PT1104306E (pt) | Composicoes de cpg e adjuvantes de saponina e seus metodos | |
SG158154A1 (en) | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
NO20023935D0 (no) | Ny, ikke-antigen, mucosal adjuvantformulering som modulerer effektene av substanser, inkludert vaksineantigener, i kontakt medmucosale kroppsoverflater | |
ATE413888T1 (de) | Salmonella vakzine | |
WO2007078879A3 (en) | Lipopeptide compositions and methods of use thereof | |
IL158428A0 (en) | Vaccine composition comprising at least one hiv virus antigen | |
AU2001284354A1 (en) | Immunological adjuvant compounds, compositions, and methods of use thereof | |
AU6761301A (en) | Adjuvant composition comprising fha protein or fragment of fha protein in free form | |
ATE505482T1 (de) | Impfstoff gegen infektiöses lachsanämievirus | |
WO2002032455A3 (en) | Vaccine | |
DE60036705D1 (de) | Adjuvanskombinationen zur immunisierung und vakzine | |
DK1204420T3 (da) | Trehaloseproducerende prokaryotiske celler som vacciner | |
EP1721618A3 (de) | Proteasom-influenzavirus-impfstoffzusammensetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R082 | Change of representative |
Ref document number: 1326633 Country of ref document: EP Representative=s name: KUDLEK & GRUNERT PATENTANWAELTE PARTNERSCHAFT, DE |